AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The Company is focused on advancing its first product candidate, epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial (NTM) lung disease. Epetraborole is a boron-containing, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA, or tRNA, molecules in protein synthesis. It is focused on developing epetraborole to treat Mycobacterium avium complex (MAC). The Company’s core technology approach is based on the use of boron chemistry for its research and development initiatives. Boron has a distinctive ability to bind with biological targets through a reversible covalent bond and the potential to address biological targets that have been difficult to inhibit using traditional carbon-based molecules.